Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aurinia Pharmaceuticals Inc. maintains a presence in the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This workload is handled by 1 distinct examiner within 1 distinct art unit. This distribution indicates that the company's current patenting efforts are focused on a single point of review at the patent office.
The busiest examiner identified is HOLTZMAN, KATHERINE ANN. This individual is assigned 1 pending office action. Because the company has 1 pending action, this examiner manages the entire active workload. This means that the prosecution strategy must be specifically tailored to the requirements and preferences of this single examiner.
The fact that there is 1 distinct art unit involved suggests that the technical scope of the pending matter is narrow. Practitioners should expect a consistent examination experience, as no other examiners or art units are currently involved. This results in a streamlined but singular prosecution path within the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLTZMAN, KATHERINE ANN | 1 | 65.7% | +58.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18361775 | PROTOCOL TO MINIMIZE CALCINEURIN INHIBITOR NEPHROTOXICITY | HOLTZMAN, KATHERINE ANN | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18361775 | PROTOCOL TO MINIMIZE CALCINEURIN INHIBITOR NEPHROTOXICITY | HOLTZMAN, KATHERINE ANN | 1646 | §103 | Final Rejection | — | Pending | Jul 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial